us-gaap:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationBenefit0000856982--12-312020Q1false100000000100000000MERIT MEDICAL SYSTEMS INC5533800055213000P1YP2YP1YP2Yus-gaap:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationBenefit0000856982us-gaap:RetainedEarningsMember2020-03-310000856982us-gaap:AccumulatedTranslationAdjustmentMember2020-03-310000856982us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310000856982us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-03-310000856982us-gaap:RetainedEarningsMember2019-12-310000856982us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000856982us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000856982us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310000856982us-gaap:RetainedEarningsMember2019-03-310000856982us-gaap:AccumulatedTranslationAdjustmentMember2019-03-310000856982us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-310000856982us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-03-310000856982us-gaap:RetainedEarningsMember2018-12-310000856982us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310000856982us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000856982us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-12-310000856982us-gaap:EmployeeStockOptionMember2019-01-012019-03-310000856982srt:MinimumMemberus-gaap:PerformanceSharesMember2020-01-012020-03-310000856982srt:MinimumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-03-310000856982srt:MaximumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-03-310000856982srt:MinimumMemberus-gaap:EmployeeStockOptionMember2019-01-012019-03-310000856982srt:MaximumMemberus-gaap:EmployeeStockOptionMember2019-01-012019-03-310000856982us-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-01-012020-03-310000856982us-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-01-012020-03-310000856982us-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2020-01-012020-03-310000856982mmsi:CashSettledPerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-01-012020-03-310000856982mmsi:CashSettledPerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-01-012020-03-310000856982mmsi:CashSettledPerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2020-01-012020-03-310000856982mmsi:FibroveinHoldingsLimitedMember2020-01-012020-03-310000856982mmsi:BrightwaterMedicalInc.Member2020-01-012020-03-310000856982mmsi:STDPharmaceuticalProductsLimitedMembermmsi:FibroveinHoldingsLimitedMember2019-08-012019-08-010000856982mmsi:PeripheralInterventionMemberus-gaap:NonUsMembermmsi:CardiovascularSegmentMember2020-01-012020-03-310000856982mmsi:PeripheralInterventionMembercountry:USmmsi:CardiovascularSegmentMember2020-01-012020-03-310000856982mmsi:OEMMemberus-gaap:NonUsMembermmsi:CardiovascularSegmentMember2020-01-012020-03-310000856982mmsi:OEMMembercountry:USmmsi:CardiovascularSegmentMember2020-01-012020-03-310000856982mmsi:EndoscopyDevicesMemberus-gaap:NonUsMembermmsi:EndoscopySegmentMember2020-01-012020-03-310000856982mmsi:EndoscopyDevicesMembercountry:USmmsi:EndoscopySegmentMember2020-01-012020-03-310000856982mmsi:CustomProceduralSolutionsMemberus-gaap:NonUsMembermmsi:CardiovascularSegmentMember2020-01-012020-03-310000856982mmsi:CustomProceduralSolutionsMembercountry:USmmsi:CardiovascularSegmentMember2020-01-012020-03-310000856982mmsi:CardiacInterventionMemberus-gaap:NonUsMembermmsi:CardiovascularSegmentMember2020-01-012020-03-310000856982mmsi:CardiacInterventionMembercountry:USmmsi:CardiovascularSegmentMember2020-01-012020-03-310000856982us-gaap:NonUsMembermmsi:CardiovascularSegmentMember2020-01-012020-03-310000856982mmsi:PeripheralInterventionMembermmsi:CardiovascularSegmentMember2020-01-012020-03-310000856982mmsi:OEMMembermmsi:CardiovascularSegmentMember2020-01-012020-03-310000856982mmsi:EndoscopyDevicesMembermmsi:EndoscopySegmentMember2020-01-012020-03-310000856982mmsi:CustomProceduralSolutionsMembermmsi:CardiovascularSegmentMember2020-01-012020-03-310000856982mmsi:CardiacInterventionMembermmsi:CardiovascularSegmentMember2020-01-012020-03-310000856982country:USmmsi:CardiovascularSegmentMember2020-01-012020-03-310000856982us-gaap:NonUsMember2020-01-012020-03-310000856982country:US2020-01-012020-03-310000856982mmsi:PeripheralInterventionMemberus-gaap:NonUsMembermmsi:CardiovascularSegmentMember2019-01-012019-03-310000856982mmsi:PeripheralInterventionMembercountry:USmmsi:CardiovascularSegmentMember2019-01-012019-03-310000856982mmsi:OEMMemberus-gaap:NonUsMembermmsi:CardiovascularSegmentMember2019-01-012019-03-310000856982mmsi:OEMMembercountry:USmmsi:CardiovascularSegmentMember2019-01-012019-03-310000856982mmsi:EndoscopyDevicesMemberus-gaap:NonUsMembermmsi:EndoscopySegmentMember2019-01-012019-03-310000856982mmsi:EndoscopyDevicesMembercountry:USmmsi:EndoscopySegmentMember2019-01-012019-03-310000856982mmsi:CustomProceduralSolutionsMemberus-gaap:NonUsMembermmsi:CardiovascularSegmentMember2019-01-012019-03-310000856982mmsi:CustomProceduralSolutionsMembercountry:USmmsi:CardiovascularSegmentMember2019-01-012019-03-310000856982mmsi:CardiacInterventionMemberus-gaap:NonUsMembermmsi:CardiovascularSegmentMember2019-01-012019-03-310000856982mmsi:CardiacInterventionMembercountry:USmmsi:CardiovascularSegmentMember2019-01-012019-03-310000856982us-gaap:NonUsMembermmsi:CardiovascularSegmentMember2019-01-012019-03-310000856982mmsi:PeripheralInterventionMembermmsi:CardiovascularSegmentMember2019-01-012019-03-310000856982mmsi:OEMMembermmsi:CardiovascularSegmentMember2019-01-012019-03-310000856982mmsi:EndoscopyDevicesMembermmsi:EndoscopySegmentMember2019-01-012019-03-310000856982mmsi:CustomProceduralSolutionsMembermmsi:CardiovascularSegmentMember2019-01-012019-03-310000856982mmsi:CardiacInterventionMembermmsi:CardiovascularSegmentMember2019-01-012019-03-310000856982country:USmmsi:CardiovascularSegmentMember2019-01-012019-03-310000856982us-gaap:NonUsMember2019-01-012019-03-310000856982country:US2019-01-012019-03-310000856982mmsi:FibroveinHoldingsLimitedMember2019-08-012019-08-010000856982us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2020-01-012020-03-310000856982us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2020-01-012020-03-310000856982us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2019-01-012019-03-310000856982us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2019-01-012019-03-310000856982mmsi:NvisionvleImagingSystemMember2019-01-012019-03-310000856982mmsi:EndoscopySegmentMember2020-01-012020-03-310000856982mmsi:EndoscopySegmentMember2019-01-012019-03-310000856982mmsi:CardiovascularSegmentMember2019-01-012019-03-310000856982us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-03-310000856982us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310000856982us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-03-310000856982us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-03-310000856982us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-310000856982us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-01-012019-03-310000856982us-gaap:RetainedEarningsMember2020-01-012020-03-310000856982us-gaap:RetainedEarningsMember2019-01-012019-03-310000856982mmsi:CreditAgreementMember2019-12-310000856982mmsi:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2020-03-310000856982mmsi:UnitedStatesDepartmentOfJusticeMatterMember2020-01-012020-03-310000856982mmsi:UnitedStatesDepartmentOfJusticeMatterMember2019-01-012019-03-310000856982mmsi:NvisionvleImagingSystemMember2020-01-012020-03-310000856982us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-03-310000856982us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000856982mmsi:InProcessTechnologyMember2020-03-310000856982mmsi:InProcessTechnologyMember2019-12-310000856982us-gaap:TrademarksMember2020-03-310000856982us-gaap:PatentsMember2020-03-310000856982us-gaap:OtherIntangibleAssetsMember2020-03-310000856982us-gaap:LicensingAgreementsMember2020-03-310000856982us-gaap:DistributionRightsMember2020-03-310000856982us-gaap:DevelopedTechnologyRightsMember2020-03-310000856982us-gaap:CustomerListsMember2020-03-310000856982us-gaap:TrademarksMember2019-12-310000856982us-gaap:PatentsMember2019-12-310000856982us-gaap:OtherIntangibleAssetsMember2019-12-310000856982us-gaap:NoncompeteAgreementsMember2019-12-310000856982us-gaap:LicensingAgreementsMember2019-12-310000856982us-gaap:DistributionRightsMember2019-12-310000856982us-gaap:DevelopedTechnologyRightsMember2019-12-310000856982us-gaap:CustomerListsMember2019-12-310000856982mmsi:ContingentConsiderationMember2020-03-310000856982mmsi:ContingentConsiderationMember2019-12-310000856982mmsi:ContingentConsiderationMember2019-03-310000856982mmsi:ContingentConsiderationMember2018-12-310000856982mmsi:ContingentConsiderationMember2019-01-012019-03-310000856982mmsi:ContingentReceivableMembermmsi:ContingentConsiderationMember2019-01-012019-03-310000856982mmsi:SelioMedicalLimitedSelioMember2019-10-110000856982us-gaap:EmployeeStockOptionMember2020-01-012020-03-310000856982us-gaap:PerformanceSharesMember2020-03-310000856982us-gaap:EmployeeStockOptionMember2020-03-310000856982mmsi:CashSettledPerformanceSharesMember2020-03-310000856982us-gaap:ForeignExchangeForwardMember2020-01-012020-03-310000856982us-gaap:ForeignExchangeForwardMemberus-gaap:FairValueHedgingMemberus-gaap:NondesignatedMember2019-12-310000856982us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000856982mmsi:WellsFargoFixedRateDerivativeContractTwoMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-230000856982mmsi:WellsFargoFixedRateDerivativeContractOneMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2016-08-050000856982us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2020-01-012020-03-310000856982us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-01-012020-03-310000856982us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-03-310000856982us-gaap:CashFlowHedgingMemberus-gaap:CostOfGoodsTotalMember2020-01-012020-03-310000856982us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2019-01-012019-03-310000856982us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2019-01-012019-03-310000856982us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:RevenueFromContractWithCustomerMember2019-01-012019-03-310000856982us-gaap:CashFlowHedgingMemberus-gaap:CostOfGoodsTotalMember2019-01-012019-03-310000856982mmsi:WellsFargoFixedRateDerivativeContractTwoMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LondonInterbankOfferedRateLiborSwapRateMember2019-12-230000856982mmsi:WellsFargoFixedRateDerivativeContractOneMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LondonInterbankOfferedRateLiborSwapRateMember2016-08-050000856982us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-03-310000856982us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-03-310000856982us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2020-03-310000856982us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-03-310000856982us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000856982us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000856982us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2019-12-310000856982us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000856982us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2020-03-310000856982us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-03-310000856982us-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-03-310000856982us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2019-12-310000856982us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000856982us-gaap:OtherNoncurrentAssetsMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000856982us-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000856982mmsi:WellsFargoFixedRateDerivativeContractOneMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-03-310000856982mmsi:WellsFargoFixedRateDerivativeContractOneMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000856982mmsi:WellsFargoFixedRateDerivativeContractTwoMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000856982mmsi:CreditAgreementMemberus-gaap:LoansPayableMember2020-03-310000856982us-gaap:RevolvingCreditFacilityMember2020-03-310000856982us-gaap:LoansPayableMember2020-03-310000856982mmsi:CreditAgreementMember2020-03-310000856982us-gaap:RevolvingCreditFacilityMember2019-12-310000856982us-gaap:LoansPayableMember2019-12-310000856982us-gaap:AccountingStandardsUpdate201613Memberus-gaap:RetainedEarningsMember2020-01-012020-03-310000856982us-gaap:AccountingStandardsUpdate201613Member2020-01-012020-03-310000856982us-gaap:AccountingStandardsUpdate201602Memberus-gaap:RetainedEarningsMember2019-01-012019-03-310000856982us-gaap:AccountingStandardsUpdate201602Member2019-01-012019-03-310000856982us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310000856982us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-03-310000856982us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-310000856982us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-01-012019-03-310000856982us-gaap:CommonStockMember2020-03-310000856982us-gaap:CommonStockMember2019-12-310000856982us-gaap:CommonStockMember2019-03-310000856982us-gaap:CommonStockMember2018-12-3100008569822019-03-3100008569822018-12-310000856982mmsi:FibroveinHoldingsLimitedMemberus-gaap:DevelopedTechnologyRightsMember2019-08-010000856982mmsi:BrightwaterMedicalInc.Memberus-gaap:TrademarksMember2019-06-140000856982mmsi:BrightwaterMedicalInc.Memberus-gaap:DevelopedTechnologyRightsMember2019-06-140000856982mmsi:BrightwaterMedicalInc.Memberus-gaap:CustomerListsMember2019-06-140000856982srt:WeightedAverageMembermmsi:RevenueMilestonesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:IncomeApproachValuationTechniqueMember2020-03-310000856982srt:WeightedAverageMembermmsi:RevenueBasedPaymentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:IncomeApproachValuationTechniqueMember2020-03-310000856982srt:MinimumMembermmsi:RevenueMilestonesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:IncomeApproachValuationTechniqueMember2020-03-310000856982srt:MinimumMembermmsi:RevenueBasedPaymentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:IncomeApproachValuationTechniqueMember2020-03-310000856982srt:MaximumMembermmsi:RevenueMilestonesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:IncomeApproachValuationTechniqueMember2020-03-310000856982srt:MaximumMembermmsi:RevenueBasedPaymentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:IncomeApproachValuationTechniqueMember2020-03-310000856982mmsi:RegulatoryApprovalMilestoneMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:IncomeApproachValuationTechniqueMember2020-03-310000856982mmsi:RegulatoryApprovalMilestoneMemberus-gaap:FairValueInputsLevel3Membermmsi:MilestonePaymentProbabilityMemberus-gaap:IncomeApproachValuationTechniqueMember2020-03-310000856982srt:MinimumMembermmsi:RevenueMilestonesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:IncomeApproachValuationTechniqueMember2019-12-310000856982srt:MinimumMembermmsi:RevenueBasedPaymentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:IncomeApproachValuationTechniqueMember2019-12-310000856982srt:MaximumMembermmsi:RevenueMilestonesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:IncomeApproachValuationTechniqueMember2019-12-310000856982srt:MaximumMembermmsi:RevenueBasedPaymentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:IncomeApproachValuationTechniqueMember2019-12-310000856982mmsi:RegulatoryApprovalMilestoneMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:IncomeApproachValuationTechniqueMember2019-12-310000856982us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-03-310000856982us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310000856982mmsi:RevenueMilestonesMemberus-gaap:FairValueInputsLevel3Member2020-03-310000856982mmsi:RevenueBasedPaymentsMemberus-gaap:FairValueInputsLevel3Member2020-03-310000856982mmsi:RegulatoryApprovalMilestoneMemberus-gaap:FairValueInputsLevel3Member2020-03-310000856982us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000856982us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000856982mmsi:RevenueMilestonesMemberus-gaap:FairValueInputsLevel3Member2019-12-310000856982mmsi:RevenueBasedPaymentsMemberus-gaap:FairValueInputsLevel3Member2019-12-310000856982mmsi:RegulatoryApprovalMilestoneMemberus-gaap:FairValueInputsLevel3Member2019-12-310000856982srt:MaximumMembermmsi:BrightwaterMedicalInc.Membermmsi:AchievementOfSalesMilestonesMember2019-06-140000856982srt:MaximumMembermmsi:BrightwaterMedicalInc.Membermmsi:AchievementOfCECertificationMember2019-06-140000856982mmsi:BluegrassVascularTechnologiesIncMember2020-01-012020-03-310000856982us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-03-310000856982us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-03-310000856982us-gaap:CostOfSalesMember2020-01-012020-03-310000856982mmsi:CashSettledPerformanceSharesMember2020-01-012020-03-310000856982us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-03-310000856982us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-03-310000856982us-gaap:CostOfSalesMember2019-01-012019-03-310000856982us-gaap:CommonStockMember2019-01-012019-03-310000856982mmsi:FibroveinHoldingsLimitedMemberus-gaap:DevelopedTechnologyRightsMember2019-08-012019-08-010000856982mmsi:BrightwaterMedicalInc.Memberus-gaap:TrademarksMember2019-06-142019-06-140000856982mmsi:BrightwaterMedicalInc.Memberus-gaap:DevelopedTechnologyRightsMember2019-06-142019-06-140000856982mmsi:BrightwaterMedicalInc.Memberus-gaap:CustomerListsMember2019-06-142019-06-140000856982us-gaap:CommonStockMember2020-01-012020-03-310000856982us-gaap:EmployeeStockOptionMember2020-01-012020-03-310000856982us-gaap:PerformanceSharesMember2020-01-012020-03-310000856982srt:MinimumMemberus-gaap:PerformanceSharesMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2020-01-012020-03-310000856982srt:MinimumMemberus-gaap:PerformanceSharesMemberus-gaap:MarketApproachValuationTechniqueMember2020-01-012020-03-310000856982srt:MaximumMemberus-gaap:PerformanceSharesMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2020-01-012020-03-310000856982srt:MaximumMemberus-gaap:PerformanceSharesMemberus-gaap:MarketApproachValuationTechniqueMember2020-01-012020-03-310000856982srt:MaximumMemberus-gaap:PerformanceSharesMember2020-01-012020-03-310000856982srt:MaximumMembermmsi:CashSettledPerformanceSharesMember2020-01-012020-03-310000856982mmsi:SelioMedicalLimitedSelioMember2019-10-112019-10-110000856982mmsi:CardiovascularSegmentMember2020-01-012020-03-310000856982mmsi:SelioMedicalLimitedSelioMember2020-03-310000856982srt:MaximumMembermmsi:SelioMedicalLimitedSelioMember2020-03-310000856982mmsi:CreditAgreementMember2020-01-012020-03-3100008569822020-03-3100008569822019-12-310000856982mmsi:ContingentConsiderationMember2020-01-012020-03-310000856982us-gaap:ForeignExchangeForwardMemberus-gaap:FairValueHedgingMemberus-gaap:NondesignatedMember2020-03-310000856982us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-03-310000856982us-gaap:InterestExpenseMember2020-01-012020-03-310000856982mmsi:RevenueAndCostOfSalesMember2020-01-012020-03-310000856982mmsi:OtherLongTermObligationsMember2020-03-310000856982mmsi:OtherLongTermObligationsMember2019-12-310000856982us-gaap:AccruedLiabilitiesMember2020-03-310000856982us-gaap:AccruedLiabilitiesMember2019-12-310000856982mmsi:FibroveinHoldingsLimitedMember2019-08-010000856982mmsi:BrightwaterMedicalInc.Member2019-06-140000856982mmsi:BrightwaterMedicalInc.Member2019-06-142019-06-1400008569822019-01-012019-03-3100008569822020-05-0500008569822020-01-012020-03-31xbrli:sharesiso4217:USDmmsi:DerivativeInstrumentxbrli:pureiso4217:EURmmsi:itemiso4217:USDxbrli:sharesmmsi:segment

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED                           March 31, 2020

OR

    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM                TO                     .

Commission File Number   0-18592

Graphic

MERIT MEDICAL SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Utah

    

87-0447695

(State or other jurisdiction of incorporation or organization)

(IRS Employer Identification No.)

1600 West Merit Parkway, South Jordan, Utah 84095

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (801) 253-1600

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of exchange on which registered

Common Stock, no par

MMSI

NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days. Yes   No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes   No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer 

Accelerated Filer 

Non-Accelerated Filer 

Smaller Reporting Company 

Emerging Growth Company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No

Indicate the number of shares outstanding of each of the Registrant’s classes of common stock, as of the latest practicable date.

Common Stock

    

55,384,036

Title or class

Number of Shares
Outstanding at May 5, 2020

Table of Contents

TABLE OF CONTENTS

PART I.

   

FINANCIAL INFORMATION

3

Item 1.

Financial Statements (Unaudited)

3

Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019

3

Consolidated Statements of Income (Loss) for the three months ended March 31, 2020 and 2019

5

Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2020 and 2019

6

Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2020 and 2019

7

Consolidated Statements of Cash Flows for the three months ended March 31, 2020 and 2019

8

Condensed Notes to Consolidated Financial Statements

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

28

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

36

Item 4.

Controls and Procedures

37

PART II.

OTHER INFORMATION

39

Item 1.

Legal Proceedings

39

Item 1A.

Risk Factors

39

Item 6.

Exhibits

42

SIGNATURES

43

Table of Contents

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

MARCH 31, 2020 AND DECEMBER 31, 2019

(In thousands)

    

March 31, 

    

December 31, 

    

2020

    

2019

ASSETS

 

(unaudited)

 

  

CURRENT ASSETS:

 

  

 

  

Cash and cash equivalents

$

50,080

$

44,320

Trade receivables — net of allowance for uncollectible accounts — 2020 — $4,124 and 2019 — $3,108

 

150,050

 

155,365

Other receivables

 

9,246

 

10,016

Inventories

 

227,776

 

225,698

Prepaid expenses and other current assets

 

16,284

 

12,497

Prepaid income taxes

 

3,486

 

3,491

Income tax refund receivables

 

5,586

 

3,151

Total current assets

 

462,508

 

454,538

PROPERTY AND EQUIPMENT:

 

  

 

  

Land and land improvements

 

27,695

 

27,554

Buildings

 

153,896

 

153,863

Manufacturing equipment

 

247,878

 

244,368

Furniture and fixtures

 

58,955

 

57,623

Leasehold improvements

 

43,950

 

43,311

Construction-in-progress

 

91,802

 

83,685

Total property and equipment

 

624,176

 

610,404

Less accumulated depreciation

 

(239,316)

 

(231,619)

Property and equipment — net

 

384,860

378,785

OTHER ASSETS:

 

  

 

  

Intangible assets:

 

  

 

  

Developed technology — net of accumulated amortization —2020 — $162,135 and 2019 — $149,947

 

366,551

 

379,529

Other — net of accumulated amortization — 2020 — $59,934 and 2019 — $65,607

 

63,693

 

65,783

Goodwill

 

352,242

 

353,193

Deferred income tax assets

 

3,716

 

3,788

Right-of-use operating lease assets

79,133

80,244

Other assets

 

36,569

 

41,461

Total other assets

 

901,904

 

923,998

TOTAL ASSETS

$

1,749,272

$

1,757,321

See condensed notes to consolidated financial statements.

(continued)

3

Table of Contents

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

MARCH 31, 2020 AND DECEMBER 31, 2019

(In thousands)

    

March 31, 

    

December 31, 

    

2020

    

2019

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

(unaudited)

    

  

CURRENT LIABILITIES:

 

  

  

Trade payables

$

56,012

$

54,623

Accrued expenses

 

87,095

 

105,184

Current portion of long-term debt

 

7,500

 

7,500

Short-term operating lease liabilities

11,670

11,550

Income taxes payable

 

3,014

 

2,799

Total current liabilities

 

165,291

 

181,656

LONG-TERM DEBT

 

438,137

 

431,984

DEFERRED INCOME TAX LIABILITIES

 

45,027

 

45,236

LONG-TERM INCOME TAXES PAYABLE

 

347

 

347

LIABILITIES RELATED TO UNRECOGNIZED TAX BENEFITS

 

1,990

 

1,990

DEFERRED COMPENSATION PAYABLE

 

14,066

 

14,855

DEFERRED CREDITS

 

2,088

 

2,122

LONG-TERM OPERATING LEASE LIABILITIES

71,642

 

72,714

OTHER LONG-TERM OBLIGATIONS

 

70,886

 

56,473

Total liabilities

 

809,474

 

807,377

COMMITMENTS AND CONTINGENCIES (Notes 4, 8, 9 and 10)

 

  

 

  

STOCKHOLDERS’ EQUITY:

 

  

 

  

Preferred stock — 5,000 shares authorized as of March 31, 2020 and December 31, 2019; no shares issued

 

 

Common stock, no par value; shares authorized — 2020 and 2019 - 100,000; issued and outstanding as of March 31, 2020 - 55,338 and December 31, 2019 - 55,213

 

590,065

 

587,017

Retained earnings

 

364,492

 

368,221

Accumulated other comprehensive loss

 

(14,759)

 

(5,294)

Total stockholders’ equity

 

939,798

 

949,944

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$

1,749,272

$

1,757,321

See condensed notes to consolidated financial statements.

(concluded)

4

Table of Contents

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME (LOSS)

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(In thousands, except per share amounts - unaudited)

    

Three Months Ended

March 31, 

    

2020

    

2019

NET SALES

$

243,525

$

238,349

COST OF SALES

 

139,741

 

133,713

GROSS PROFIT

 

103,784

 

104,636

OPERATING EXPENSES:

 

  

 

  

Selling, general and administrative

 

78,808

 

78,270

Research and development

 

14,872

 

16,043

Impairment and other charges

 

3,845

 

Contingent consideration expense

 

4,897

 

775

Acquired in-process research and development

 

 

25

Total operating expenses

 

102,422

 

95,113

INCOME FROM OPERATIONS

 

1,362

 

9,523

OTHER INCOME (EXPENSE):

 

  

 

  

Interest income

 

79

 

357

Interest expense

 

(3,144)

 

(2,764)

Other expense - net

 

(289)

 

(270)

Total other expense — net

 

(3,354)

 

(2,677)

INCOME (LOSS) BEFORE INCOME TAXES

 

(1,992)

 

6,846

INCOME TAX EXPENSE

 

1,162

 

651

NET INCOME (LOSS)

$

(3,154)

$

6,195

EARNINGS (LOSS) PER COMMON SHARE:

 

  

 

  

Basic

$

(0.06)

$

0.11

Diluted

$

(0.06)

$

0.11

AVERAGE COMMON SHARES:

 

  

 

  

Basic

 

55,246

 

54,917

Diluted

 

55,246

 

56,490

See condensed notes to consolidated financial statements.

5

Table of Contents

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(In thousands - unaudited)

    

Three Months Ended

March 31, 

    

2020

    

2019

Net income (loss)

$

(3,154)

$

6,195

Other comprehensive income (loss):

 

  

 

  

Cash flow hedges

 

(7,182)

 

(2,577)

Income tax benefit (expense)

 

1,849

 

663

Foreign currency translation adjustment

 

(4,125)

 

(615)

Income tax benefit (expense)

 

(7)

 

14

Total other comprehensive loss

 

(9,465)

 

(2,515)

Total comprehensive income (loss)

$

(12,619)

$

3,680

See condensed notes to consolidated financial statements.

6

Table of Contents

MERIT MEDICAL SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(In thousands - unaudited)

Accumulated Other

Common Stock

Retained

Comprehensive

    

Total

    

Shares

    

Amount

    

Earnings

    

Income (Loss)

BALANCE — January 1, 2020

$

949,944

 

55,213

$

587,017

$

368,221

$

(5,294)

Net loss

 

(3,154)

 

  

 

  

 

(3,154)

 

  

Cumulative effect adjustment upon adoption of ASU 2016-13, Credit Losses

(575)

(575)

Other comprehensive loss

 

(9,465)

 

  

 

  

 

  

 

(9,465)

Stock-based compensation expense

 

2,641

 

  

 

2,641

 

  

 

  

Options exercised

 

2,369

 

174

 

2,369

 

  

 

  

Issuance of common stock under Employee Stock Purchase Plan

 

371

 

13

 

371

 

  

 

  

Shares surrendered in exchange for payment of payroll tax liabilities

(866)

 

(23)

 

(866)

Shares surrendered in exchange for exercise of stock options

(1,467)

 

(39)

 

(1,467)

BALANCE — March 31, 2020

$

939,798

 

55,338

$

590,065

$

364,492

$

(14,759)

Accumulated Other

Common Stock

Retained

Comprehensive

    

Total

    

Shares

    

Amount

    

Earnings

    

Income (Loss)

BALANCE — January 1, 2019

$

932,775

54,893

$

571,383

$

363,425

$

(2,033)

Net income

 

6,195

 

  

 

  

 

6,195

 

  

Reclassify deferred gain on sale-leaseback upon adoption of ASC 842

93

93

Other comprehensive loss

 

(2,515)

 

  

 

  

 

  

 

(2,515)

Stock-based compensation expense

 

1,766

 

  

 

1,766

 

  

 

  

Options exercised

 

1,365

 

95

 

1,365

 

  

 

  

Issuance of common stock under Employee Stock Purchase Plan

 

432

 

7

 

432

 

  

 

  

BALANCE — March 31, 2019

$

940,111

 

54,995

$

574,946

$

369,713

$

(4,548)

See condensed notes to consolidated financial statements.

7

Table of Contents

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(In thousands - unaudited)

Three Months Ended

March 31, 

    

2020

    

2019

CASH FLOWS FROM OPERATING ACTIVITIES:

 

  

 

  

Net income (loss)

$

(3,154)

$

6,195

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

  

 

  

Depreciation and amortization

 

23,320

 

22,348

Loss on sales and/or abandonment of property and equipment

 

37

 

288

Write-off of certain intangible assets and other long-term assets

 

3,925

 

Acquired in-process research and development

 

 

25

Amortization of right-of-use operating lease assets

3,134

2,964

Fair value adjustments to contingent consideration

4,897

775

Amortization of deferred credits

 

(35)

 

(35)

Amortization of long-term debt issuance costs

 

151

 

201

Stock-based compensation expense

 

2,777

 

1,766

Changes in operating assets and liabilities, net of effects from acquisitions:

 

 

  

Trade receivables

 

3,445

 

(11,557)

Other receivables

 

613

 

1,090

Inventories

 

(4,983)

 

(1,340)

Prepaid expenses and other current assets

 

(3,126)

 

19

Prepaid income taxes

 

 

(53)

Income tax refund receivables

 

(2,475)

 

(442)

Other assets

 

(577)

 

(2,092)

Trade payables

 

4,340

 

(878)

Accrued expenses

 

(1,621)

 

(2,976)

Income taxes payable

 

2,109

 

(879)

Deferred compensation payable

 

(789)

 

1,261

Operating lease liabilities

(2,945)

(3,054)

Other long-term obligations

 

(179)

 

(121)

Total adjustments

 

32,018

 

7,310

Net cash provided by operating activities

 

28,864

 

13,505

CASH FLOWS FROM INVESTING ACTIVITIES:

 

  

 

  

Capital expenditures for:

 

  

 

  

Property and equipment

 

(13,950)

 

(18,255)

Intangible assets

 

(1,062)

 

(853)

Proceeds from the sale of property and equipment

 

 

3

Cash received for settlement of current note receivable

 

250

 

Cash paid in acquisitions, net of cash acquired

 

 

(1,942)

Net cash used in investing activities

 

(14,762)

 

(21,047)

See condensed notes to consolidated financial statements.

(continued)

8

Table of Contents

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(In thousands - unaudited)

    

Three Months Ended

March 31, 

2020

2019

CASH FLOWS FROM FINANCING ACTIVITIES:

 

  

 

  

Proceeds from issuance of common stock

$

1,261

$

1,733

Proceeds from issuance of long-term debt

 

30,665

 

43,119

Payments on long-term debt

(24,540)

(54,119)

Contingent payments related to acquisitions

 

(12,754)

 

(554)

Payment of taxes related to an exchange of common stock

 

(866)

 

Net cash used in financing activities

 

(6,234)

 

(9,821)

EFFECT OF EXCHANGE RATES ON CASH

 

(2,108)

 

(474)

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

 

5,760

 

(17,837)

CASH AND CASH EQUIVALENTS:

 

  

 

  

Beginning of period

 

44,320

 

67,359

End of period

$

50,080

$

49,522

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION

 

  

 

  

Cash paid during the period for:

 

  

 

  

Interest (net of capitalized interest of $392 and $241, respectively)

$

3,198

$

2,721

Income taxes

$

1,637

$

1,934

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES

 

  

 

  

Property and equipment purchases in accounts payable

$

5,383

$

4,588

Current note receivable converted to equity investment

$

899

$

Right-of-use operating lease assets obtained in exchange for operating lease liabilities

$

2,800

$

1,162

See condensed notes to consolidated financial statements.

(concluded)

9

Table of Contents

MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.   Basis of Presentation. The interim consolidated financial statements of Merit Medical Systems, Inc. ("Merit," "we" or "us") for the three months ended March 31, 2020 and 2019 are not audited. Our consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods and, consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America. In the opinion of our management, the accompanying consolidated financial statements contain all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial position as of March 31, 2020 and December 31, 2019, and our results of operations and cash flows for the three-month periods ended March 31, 2020 and 2019. The results of operations for the three-month periods ended March 31, 2020 and 2019 are not necessarily indicative of the results for a full-year period. Within the financial statements and tables presented, certain columns and rows may not total due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. These interim consolidated financial statements should be read in conjunction with the financial statements included in our Annual Report on Form 10-K (the "2019 Form 10-K") for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission (the "SEC") on March 2, 2020.

Reclassifications

Certain reclassifications have been made to the 2019 periods to conform to the 2020 presentation. In the consolidated statements of cash flows, the fair value adjustment to contingent consideration is presented as a reconciling item between net income (loss) and cash flows from operating activities in 2020, with a corresponding reclassification of $775,000 made in the prior period for comparability, along with corresponding reclassifications to the change in certain operating assets and liabilities.

2.   Recently Issued Financial Accounting Standards.

Recently Adopted

In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). ASU 2018-15 became effective for us on January 1, 2020. The adoption of this standard did not have a material impact on our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820), which removes, modifies and adds various disclosure requirements related to fair value disclosures. ASU 2018-13 became effective for us beginning on January 1, 2020. We modified our disclosures beginning in the three-month period ended March 31, 2020 to conform with this guidance (see Note 14).

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaced the incurred loss impairment methodology for financial assets with a methodology that reflects expected credit losses. The new credit loss model must be applied to loans, accounts receivable, and other financial assets. ASU 2016-13 became effective for us beginning on January 1, 2020. We adopted this standard using a modified retrospective approach with a cumulative-effect adjustment to retained earnings of $575,000 as of the beginning of 2020. See Note 14 for additional disclosures related to our allowance for current expected credit losses. The adoption of this guidance did not have a material impact on our statements of operations or cash flows.

We currently believe that all other issued and not yet effective accounting standards are not relevant to our financial statements.

10

Table of Contents

3.   Revenue from Contracts with Customers. We recognize revenue when a customer obtains control of promised goods. The amount of revenue recognized reflects the consideration we expect to receive in exchange for these goods.

Disaggregation of Revenue

The disaggregation of revenue is based on product category and geographical region. Beginning in the first quarter of 2020, we revised our product categories to more clearly reflect how we sell our products to our customers. We presented historical information under the new revised product categories in a Current Report on Form 8-K, filed with the SEC on April 3, 2020.

We design, develop, manufacture and market medical products for interventional and diagnostic procedures. For financial reporting purposes, we report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and OEM. Within these product categories, we sell a variety of products, including cardiology and radiology devices (which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases), as well as embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, interventional oncology and spine devices. Our endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors.

The following tables present revenue from contracts with customers for the three-month periods ended March 31, 2020 and 2019 (in thousands):

Three Months Ended

Three Months Ended

March 31, 2020

March 31, 2019

    

United States

    

International

    

Total

    

United States

    

International

    

Total

Cardiovascular

 

  

 

  

 

  

 

  

 

  

 

  

Peripheral Intervention

$

55,803

$

31,272

$

87,075

$

55,600

$

29,033

$

84,633

Cardiac Intervention

 

28,595

43,996

 

72,591

 

27,016

 

45,524

 

72,540

Custom Procedural Solutions

 

25,414

22,207

 

47,621

 

23,815

 

22,046

 

45,861

OEM

 

23,666

4,591

 

28,257

 

24,061

 

3,385

 

27,446

Total

 

133,478

102,066

 

235,544

 

130,492

 

99,988

 

230,480

 

Endoscopy

Endoscopy devices

 

7,578

 

403

 

7,981

 

7,568

 

301

 

7,869

Total

$

141,056

$

102,469

$

243,525

$

138,060

$

100,289

$

238,349

11

Table of Contents

4.   Acquisitions. On August 1, 2019, we entered into a share purchase agreement to acquire Fibrovein Holdings Limited, which is the owner of 100% of the capital stock of STD Pharmaceutical Products Limited, a UK private company engaged in the manufacture, distribution and sale of pharmaceutical sclerotherapy products (“STD Pharmaceutical”). The purchase consideration consisted of an upfront payment of approximately $13.7 million, net of cash acquired. We also recorded a contingent consideration liability of approximately $934,000 related to royalties potentially payable pursuant to the terms of the share purchase agreement. We accounted for this acquisition as a business combination. The sales and results of operations related to the acquisition have been included in our cardiovascular segment since the acquisition date and were not material. Acquisition-related costs associated with the STD Pharmaceutical acquisition, which were included in selling, general and administrative expenses, were not material. The purchase price was preliminarily allocated as follows (in thousands):

Assets Acquired

    

  

Trade receivables

$

277

Inventories

 

843

Prepaid expenses and other assets

 

49

Intangible assets

 

Developed technology

10,428

Goodwill

4,975

Total assets acquired

 

16,572

Liabilities Assumed

 

  

Trade payables

 

(53)

Accrued expenses

 

(29)

Deferred income tax liabilities

 

(1,890)

Total liabilities assumed

 

(1,972)

Total net assets acquired

$

14,600

We are amortizing the developed technology intangible asset acquired in the STD Pharmaceutical acquisition over 12 years. The goodwill consists largely of the synergies we hope to achieve from combining operations and is not expected to be deductible for income tax purposes.

On June 14, 2019, we consummated an acquisition transaction contemplated by a merger agreement to acquire Brightwater Medical, Inc. ("Brightwater"). The purchase consideration consisted of an upfront payment of $35 million plus a final working capital adjustment of approximately $39,000, net of cash acquired, with potential earn-out payments of up to an additional $5 million for achievement of CE certification with respect to the Brightwater ConvertX®, a single-use device used to replace a series of devices and procedures used to treat severe obstructions of the ureter, and up to an additional $10 million for the achievement of sales milestones specified in the merger agreement. The ConvertX device is designed to be implanted once and converted from a nephroureteral catheter to a nephroureteral stent without requiring sedation or local anesthesia. Brightwater recently received FDA clearance for the ConvertX biliary stent device. We accounted for this acquisition as a business combination. The sales and results of operations related to the acquisition have been included in our cardiovascular segment since the acquisition date and were not material. Acquisition-related costs associated with

12

Table of Contents

the Brightwater acquisition, which were included in selling, general and administrative expenses, were not material. The purchase price was preliminarily allocated as follows (in thousands):

Assets Acquired

    

Trade receivables

$

55

Inventories

 

349

Property and equipment

 

409

Other long-term assets

 

30

Intangible assets

 

  

Developed technology

 

31,960

Customer lists

 

83

Trademarks

 

250

Goodwill

 

17,492

Total assets acquired

 

50,628

Liabilities Assumed

 

  

Trade payables

 

(58)

Accrued expenses

 

(261)

Other long-term obligations

 

(1,522)

Deferred income tax liabilities

 

(4,148)

Total liabilities assumed

 

(5,989)

Total net assets acquired

$

44,639

We are amortizing the developed technology intangible asset acquired in the Brightwater acquisition over 13 years, the related trademarks over five years and the customer list on an accelerated basis over one year. The total weighted-average amortization period for these acquired intangible assets is approximately 12.9 years. The goodwill consists largely of the synergies and economies of scale we hope to achieve from combining the acquired assets and operations with our historical operations and is not expected to be deductible for income tax purposes.

The pro forma impact of these acquisitions was not significant, either individually or in the aggregate, on our financial results for the three-month period ended March 31, 2019. Operating results attributable to the STD Pharmaceutical and Brightwater acquisitions were included in our consolidated statements of income (loss) for the three-month period ended March 31, 2020.

5. Inventories. Inventories at March 31, 2020 and December 31, 2019, consisted of the following (in thousands):

    

March 31, 2020

    

December 31, 2019

Finished goods

$

126,495

$

134,467

Work-in-process

 

24,592

 

17,602

Raw materials

 

76,689

 

73,629

Total inventories

$

227,776

$

225,698

6.   Goodwill and Intangible Assets. The changes in the carrying amount of goodwill for the three-month period ended March 31, 2020 were as follows (in thousands):

    

2020

    

Goodwill balance at January 1

$

353,193

Effect of foreign exchange

 

(951)

Goodwill balance at March 31

$

352,242

13

Table of Contents

Total accumulated goodwill impairment losses aggregated to approximately $8.3 million as of March 31, 2020 and December 31, 2019. We did not have any goodwill impairments for the three-month periods ended March 31, 2020 and 2019. The total goodwill balance as of March 31, 2020 and December 31, 2019 was related to our cardiovascular segment.

Other intangible assets at March 31, 2020 and December 31, 2019, consisted of the following (in thousands):

March 31, 2020

Gross Carrying

Accumulated

Net Carrying

    

Amount

    

Amortization

    

Amount

Patents

$

23,764

$

(7,396)

$

16,368

Distribution agreements

 

5,754

 

(4,656)

 

1,098

License agreements

 

22,017

 

(8,337)

 

13,680

Trademarks

 

30,235

 

(10,202)

 

20,033

Customer lists

 

39,357

 

(29,343)

 

10,014

In-process technology

 

2,500

 

 

2,500

Total

$

123,627

$

(59,934)

$

63,693

December 31, 2019

Gross Carrying

Accumulated

Net Carrying

    

Amount

    

Amortization

    

Amount

Patents

    

$

22,703

$

(6,863)

$

15,840

Distribution agreements

 

8,012

 

(6,794)

 

1,218

License agreements

 

26,987

 

(12,746)

 

14,241

Trademarks

 

30,240

 

(9,477)

 

20,763

Covenants not to compete

 

964

 

(964)

 

Customer lists

 

39,984

 

(28,763)

 

11,221

In-process technology

 

2,500

 

 

2,500

Total

$

131,390

$

(65,607)

$

65,783

Aggregate amortization expense for the three-month periods ended March 31, 2020 and 2019 was approximately $15.0 million and $14.8 million, respectively.

We evaluate long-lived assets, including amortizing intangible assets, for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. We perform the impairment analysis at the asset group for which the lowest level of identifiable cash flows is largely independent of the cash flows of other assets and liabilities. We compare the carrying value of the amortizing intangible assets acquired to the undiscounted cash flows expected to result from the asset group and determine whether the carrying amount is recoverable. We determine the fair value of our amortizing assets based on estimated future cash flows discounted back to their present value using a discount rate that reflects the risk profiles of the underlying activities. We did not identify indicators of impairment in any intangible assets based on our qualitative assess